TY - JOUR
T1 - CARs in chronic lymphocytic leukemia - Ready to drive
AU - Hosing, Chitra
AU - Kebriaei, Partow
AU - Wierda, William
AU - Jena, Bipulendu
AU - Cooper, Laurence J.N.
AU - Shpall, Elizabeth
N1 - Funding Information:
Acknowledgments Support from: CLL Alliance Global Foundation, MD Anderson Cancer Center Core Grant (CA16672); PO1 (CA100265); RO1 (CA124782, CA120956, CA141303, CA116127); R33 (CA116127); DOD PR064229; Disclosure C. Hosing: Received grants from Celgene, Sanofi, honoraria from Sanofi, payment for development of educational presentations including service on speakers’ bureaus from Schering-Plough and Genzyme, travel/accommodations expenses covered or reimbursed by Schering-Plough, Genzyme, Mesoblast. P. Kebriaei: nothing to disclose; W. Wierda: nothing to disclose; B. Jena: nothing to disclose; L. Cooper: received grants from NIH and CLL Global Research Foundation and he is the founder of InCellerate, Inc., which seeks to commercialize immune-based therapies; E. Shpall received a grant from Mesoblast.
PY - 2013/3
Y1 - 2013/3
N2 - Adoptive transfer of antigen-specific T cells has been adapted by investigators for treatment of chronic lymphocytic leukemia (CLL). To overcome issues of immune tolerance which limits the endogenous adaptive immune response to tumor-associated antigens (TAAs), robust systems for the genetic modification and characterization of T cells expressing chimeric antigen receptors (CARs) to redirect specificity have been produced. Refinements with regards to persistence and trafficking of the genetically modified T cells are underway to help improve potency. Clinical trials utilizing this technology demonstrate feasibility, and increasingly, these early-phase trials are demonstrating impressive anti-tumor effects, particularly for CLL patients, paving the way for multi-center trials to establish the efficacy of CAR+ T cell therapy.
AB - Adoptive transfer of antigen-specific T cells has been adapted by investigators for treatment of chronic lymphocytic leukemia (CLL). To overcome issues of immune tolerance which limits the endogenous adaptive immune response to tumor-associated antigens (TAAs), robust systems for the genetic modification and characterization of T cells expressing chimeric antigen receptors (CARs) to redirect specificity have been produced. Refinements with regards to persistence and trafficking of the genetically modified T cells are underway to help improve potency. Clinical trials utilizing this technology demonstrate feasibility, and increasingly, these early-phase trials are demonstrating impressive anti-tumor effects, particularly for CLL patients, paving the way for multi-center trials to establish the efficacy of CAR+ T cell therapy.
KW - Chimeric antigen receptor
KW - Chronic lymphocytic leukemia
KW - Gene therapy
UR - http://www.scopus.com/inward/record.url?scp=84874286123&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84874286123&partnerID=8YFLogxK
U2 - 10.1007/s11899-012-0145-y
DO - 10.1007/s11899-012-0145-y
M3 - Article
C2 - 23225251
AN - SCOPUS:84874286123
SN - 1558-8211
VL - 8
SP - 60
EP - 70
JO - Current hematologic malignancy reports
JF - Current hematologic malignancy reports
IS - 1
ER -